Tnf Pharmaceuticals Inc (TNFA)

$0.11 -0.01 (-4.23%)
Market Cap 1.68M
Revenue (ttm) 0.00
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,968,700
Avg Vol 5,387,980
Day's Range N/A - N/A
Shares Out 14.18M
Stochastic %K 23%
Beta 1.98
Analysts Strong Buy
Price Target N/A

Company Profile

TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analo...

Industry: Biotechnology
Sector: Healthcare
Phone: 856 848 8698
Address:
1185 Avenue of the Americas, Suite 249, New York, United States
DipBuyInvester
DipBuyInvester Jul. 8 at 2:22 AM
$TNFA Tomorrow will be fourth day since share price dropped significantly.. The 3-Day Rule is an informal strategy suggesting that investors should wait three days after a significant drop in a stock's price before buying shares. Looks like share price is bouncing up tomorrow. Adding more on dip before it spikes.
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 10:35 PM
$TNFA Making cup and handle curve. Setting well.
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 8:03 PM
$TNFA Upside trend begins here!!
0 · Reply
Komba
Komba Jul. 7 at 7:28 PM
$TNFA buying here
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 6:47 PM
$TNFA in dip now!!
1 · Reply
M1LL5
M1LL5 Jul. 7 at 4:57 PM
$TNFA being bled 👀
0 · Reply
SCTrader58
SCTrader58 Jul. 7 at 4:35 PM
$TNFA some of the most notorious pumpers have showed up. Beware!
0 · Reply
Ripthestock
Ripthestock Jul. 7 at 2:26 PM
$TNFA squeezing downwards
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 2:14 PM
$TNFA wtf is goin on here?
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 1:45 PM
$MBIO definitely made the wrong choice today. Hopefully $TNFA does something to make me less sick. Lol.
0 · Reply
Latest News on TNFA
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

Jun 24, 2025, 9:15 AM EDT - 13 days ago

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

May 8, 2025, 9:20 AM EDT - 2 months ago

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

Apr 22, 2025, 9:15 AM EDT - 2 months ago

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

Apr 16, 2025, 9:15 AM EDT - 2 months ago

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Mar 17, 2025, 9:15 AM EDT - 4 months ago

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Mar 5, 2025, 9:00 AM EST - 4 months ago

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

Feb 25, 2025, 9:20 AM EST - 4 months ago

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Jan 29, 2025, 9:15 AM EST - 5 months ago

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Jan 15, 2025, 9:15 AM EST - 6 months ago

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Dec 19, 2024, 9:15 AM EST - 7 months ago

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Dec 9, 2024, 9:00 AM EST - 7 months ago

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

Oct 2, 2024, 9:10 AM EDT - 9 months ago

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Aug 21, 2024, 9:00 AM EDT - 11 months ago

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

Jul 24, 2024, 9:05 AM EDT - 1 year ago

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

Jul 22, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

Jun 17, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

PMCB

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PMCB

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Mar 5, 2024, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Feb 13, 2024, 11:45 AM EST - 1 year ago

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

Dec 29, 2023, 12:45 PM EST - 1 year ago

MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Dec 6, 2023, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Oct 19, 2023, 9:00 AM EDT - 1 year ago

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

Oct 4, 2023, 7:30 AM EDT - 1 year ago

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

Aug 14, 2023, 8:30 AM EDT - 2 years ago

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

Aug 2, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

Jul 31, 2023, 9:00 AM EDT - 2 years ago

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Apr 12, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Mar 20, 2023, 8:55 AM EDT - 2 years ago

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Mar 8, 2023, 8:30 AM EST - 2 years ago

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Mar 2, 2023, 8:30 AM EST - 2 years ago

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Feb 28, 2023, 8:30 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

MyMD Announces $15 Million Offering with Existing Investors

Feb 21, 2023, 8:45 AM EST - 2 years ago

MyMD Announces $15 Million Offering with Existing Investors

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Dec 6, 2022, 9:40 AM EST - 2 years ago

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Dec 6, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Nov 17, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Nov 14, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Aug 30, 2022, 8:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Aug 3, 2022, 9:45 AM EDT - 3 years ago

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Jul 26, 2022, 7:30 AM EDT - 3 years ago

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

Jul 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Jun 21, 2022, 10:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Apr 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Apr 5, 2022, 9:15 AM EDT - 3 years ago

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

Mar 24, 2022, 9:26 AM EDT - 3 years ago

MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Feb 23, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Feb 8, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Jan 5, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Dec 29, 2021, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

ORMP

DipBuyInvester
DipBuyInvester Jul. 8 at 2:22 AM
$TNFA Tomorrow will be fourth day since share price dropped significantly.. The 3-Day Rule is an informal strategy suggesting that investors should wait three days after a significant drop in a stock's price before buying shares. Looks like share price is bouncing up tomorrow. Adding more on dip before it spikes.
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 10:35 PM
$TNFA Making cup and handle curve. Setting well.
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 8:03 PM
$TNFA Upside trend begins here!!
0 · Reply
Komba
Komba Jul. 7 at 7:28 PM
$TNFA buying here
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 6:47 PM
$TNFA in dip now!!
1 · Reply
M1LL5
M1LL5 Jul. 7 at 4:57 PM
$TNFA being bled 👀
0 · Reply
SCTrader58
SCTrader58 Jul. 7 at 4:35 PM
$TNFA some of the most notorious pumpers have showed up. Beware!
0 · Reply
Ripthestock
Ripthestock Jul. 7 at 2:26 PM
$TNFA squeezing downwards
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 2:14 PM
$TNFA wtf is goin on here?
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 1:45 PM
$MBIO definitely made the wrong choice today. Hopefully $TNFA does something to make me less sick. Lol.
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 1:23 PM
$TNFA Hope this rips like $MBIO.
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 12:40 PM
$TNFA was either this or $MBIO. As of now, wrong choice. Lol.
0 · Reply
Jwade4981
Jwade4981 Jul. 7 at 12:10 PM
$TNFA PT?
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 7 at 12:08 PM
$SVRE 85% ran this morning from 2.05 idea ✅ I’m bullish on $TNFA oversold and bottomed penny like my $VOR idea recently .14 to $2+ $RVYL momentum play
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 11:46 AM
$TNFA BTOG, CANF, WLGS
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 7 at 11:08 AM
$RVYL $SVRE $TNFA $SVRE 60% so far ✅ 2.05-2.10 swing alert Watch $TNFA and $RVYL next 🔥
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 7 at 11:08 AM
$SVRE 60% so far ✅ 2.05-2.10 swing alert Watch $TNFA and $RVYL next
1 · Reply
AlSookTraders
AlSookTraders Jul. 7 at 10:34 AM
$TNFA filled some last week, one watch today for move
0 · Reply
DipBuyInvester
DipBuyInvester Jul. 7 at 9:09 AM
$TNFA On track to run!! Get set then Go!!
0 · Reply
Firedolphin21
Firedolphin21 Jul. 7 at 8:56 AM
$SVRE $RVYL $TNFA
0 · Reply
walfofwallstreet
walfofwallstreet Jul. 6 at 5:19 PM
Monday fire 🔥list🔥🐺 $PMAX 💎 💯% 👀 $BTOG 💎 💯% 👀 $GIBO $WLGS $TNFA Huge upcoming 💰💵💰 Monday 🚀🚀🚀🚀🚀🌑 All my followers are making bank 🏦 You all gonna be rich 🤑
3 · Reply
God_Damnit
God_Damnit Jul. 6 at 3:52 PM
$BTOG $GIBO $PMAX $TNFA $WLGS I follow the Walf and so should you Fire list I'm most excited about PMAX and BTOG
1 · Reply